% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Tix:300219,
      author       = {T. Tix and M. Alhomoud and R. Shouval and G. Iacoboni and
                      E. R. Scheffer Cliff and D. K. Hansen and S. Z. Usmani and
                      G. Salles and M.-A. Perales and D. M. Cordas Dos Santos and
                      K. Rejeski$^*$},
      title        = {{N}on-relapse mortality with bispecific antibodies: {A}
                      systematic review and meta-analysis in lymphoma and multiple
                      myeloma.},
      journal      = {Molecular therapy},
      volume       = {33},
      number       = {7},
      issn         = {1525-0016},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-00681},
      pages        = {3163-3176},
      year         = {2025},
      note         = {Volume 33, Issue 7, 2 July 2025, Pages 3163-3176},
      abstract     = {Bispecific antibodies (BsAb) are associated with distinct
                      immune-related toxicities that impact morbidity and
                      mortality. This systematic review and meta-analysis examined
                      non-relapse mortality (NRM) with BsAb therapy in B-cell
                      non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). A
                      PubMed and Embase search up to October 2024 identified 29
                      studies (21 NHL, 8 MM) involving 2,535 patients. The overall
                      NRM point estimate was $4.7\%$ $(95\%$ CI $3.4-6.4\%)$ with
                      a median follow-up of 12.0 months. We noted no significant
                      difference in NRM across disease entities (NHL: $4.2\%,$ MM:
                      $6.2\%,$ p=0.22). In NHL, prespecified subgroup analyses
                      revealed increased NRM in real-world studies compared to
                      clinical trials. For MM, an association between NRM and
                      higher response rates and longer follow-up was noted.
                      Meta-regression comparing BsAb and CAR-T therapies (n=8,592)
                      showed no significant NRM difference when accounting for key
                      study-level confounders (p=0.96). Overall, infections were
                      the leading cause of NRM, accounting for $71.8\%$ of
                      non-relapse deaths. Of the infection-related deaths, $48\%$
                      were attributed to COVID-19. In a pre-specified sensitivity
                      analysis excluding COVID-19-fatalities, the overall NRM
                      estimate was $3.5\%$ $(95\%$ CI $2.6-4.6\%).$ Taken
                      together, these results provide a benchmark for the
                      estimated NRM with BsAb therapy and highlight the paramount
                      importance of infection reporting, prevention, and
                      mitigation.},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40170355},
      doi          = {10.1016/j.ymthe.2025.03.048},
      url          = {https://inrepo02.dkfz.de/record/300219},
}